Brantly, ML, Spencer, LT, Humphries, M, Conlon, TJ, Spencer, CT, Poirier, A et al.. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 1-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 17: 1177-1186

Department of Medicine, University of Florida, Gainesville, FL 32611, USA.
Human Gene Therapy (Impact Factor: 3.76). 01/2007; 17(12):1177-86. DOI: 10.1089/hum.2006.17.1177
Source: PubMed


A phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 (rAAV2) alpha1-antitrypsin (AAT) vector was performed in 12 AAT-deficient adults, 10 of whom were male. All subjects were either homozygous for the most common AAT mutation (a missense mutation designated PI*Z) or compound heterozygous for PI*Z and another mutation known to cause disease. There were four dose cohorts, ranging from 2.1 x 10(12) vector genomes (VG) to 6.9 x 10(13) VG, with three subjects per cohort. Subjects were injected sequentially in a dose-escalating fashion with a minimum of 14 days between patients. Subjects who had been receiving AAT protein replacement discontinued that therapy 28 days before vector administration. There were no vector-related serious adverse events in any of the 12 participants. Vector DNA sequences were detected in the blood between 1 and 3 days after injection in nearly all patients receiving doses of 6.9 x 10(12) VG or higher. Anti-AAV2 capsid antibodies were present and rose after vector injection, but no other immune responses were detected. One subject who had not been receiving protein replacement exhibited low-level expression of wild-type M-AAT in the serum (82 nM), which was detectable 30 days after receiving an injection of 2.1 x 10(13) VG. Unfortunately, residual but declining M-AAT levels from the washout of the protein replacement elevated background levels sufficiently to obscure any possible vector expression in that range in most of the other individuals in the higher dose cohorts.

Download full-text


Available from: Thomas J Conlon,
  • Source
    • "Recombinant AAV (rAAV) expresses no viral proteins, is able to transduce both dividing and non-dividing cells, and is associated with persistent transgene expression [19], [20]. It has been extensively evaluated as a gene therapy vector with hundreds of patients having received rAAV in clinical trials without any significant vector-associated complications [21], [22], [23], [24], [25], [26]. Unlike gamma-retroviral and lentiviral vectors, integration of rAAV is uncommon, with the vector genome persisting in an episomal state [27]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The study of melanocyte biology is important to understand their role in health and disease. However, current methods of gene transfer into melanocytes are limited by safety or efficacy. Recombinant adeno-associated virus (rAAV) has been extensively investigated as a gene therapy vector, is safe and is associated with persistent transgene expression without genome integration. There are twelve serotypes and many capsid variants of rAAV. However, a comparative study to determine which rAAV is most efficient at transducing primary human melanocytes has not been conducted. We therefore sought to determine the optimum rAAV variant for use in the in vitro transduction of primary human melanocytes, which could also be informative to future in vivo studies. We have screened eight variants of rAAV for their ability to transduce primary human melanocytes and identified rAAV6 as the optimal serotype, transducing 7-78% of cells. No increase in transduction was seen with rAAV6 tyrosine capsid mutants. The number of cells expressing the transgene peaked at 6-12 days post-infection, and transduced cells were still detectable at day 28. Therefore rAAV6 should be considered as a non-integrating vector for the transduction of primary human melanocytes.
    PLoS ONE 04/2013; 8(4):e62753. DOI:10.1371/journal.pone.0062753 · 3.23 Impact Factor
  • Source
    • "These preclinical findings suggest that rAAV gene therapy can influence neural GAA activity in Pompe disease. In addition, others have reported an acceptable safety profile for AAV1-mediated gene delivery in human clinical trials (Brantly et al., 2006; Mendell et al., 2010). As such, we initiated a phase I/II clinical trial of rAAV1-hGAA intramuscular gene transfer to the diaphragm . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Pompe Disease is an inherited neuromuscular disease due to deficiency of lysosomal acid alpha-glucosidase (GAA) leading to glycogen accumulation in muscle and motoneurons. Cardiopulmonary failure in infancy leads to early mortality and GAA enzyme replacement therapy (ERT) results in improved survival, reduction of cardiac hypertrophy and developmental gains. However, many children have progressive ventilatory insufficiency and need additional support. Preclinical work shows that gene transfer restores phrenic neural activity and corrects ventilatory deficits. Here we present 180-day safety and ventilatory outcomes for five ventilator-dependent children in a phase I/II clinical trial of AAV-mediated GAA gene therapy (rAAV1-hGAA) following intradiaphragmatic delivery. We assessed if rAAV1-hGAA results in acceptable safety outcome and detectable functional changes, using general safety measures, immunological studies and pulmonary functional testing. All subjects required chronic, full-time mechanical ventilation due to respiratory failure that was unresponsive to both ERT and pre-operative muscle conditioning exercises. After receiving a dose of either 1 x 1012 vg (n=3) or 5 x 1012 vg (n=2) of rAAV1-hGAA, the subjects' unassisted tidal volume was significantly larger (median, IQR: 28.8% increase, 15.2-35.2, p<0.05). Further most patients tolerated appreciably longer periods of unassisted breathing (425% increase, 103-851%, p=0.08). Gene transfer did not improve maximal inspiratory pressure. Expected levels of circulating antibodies and no T cell-mediated immune responses to the vector (capsids) were observed. One subject demonstrated a slight increase in anti-GAA antibody that was not considered clinically significant. These results indicate that rAAV1-hGAA was safe and may lead to modest improvements in volitional ventilatory performance measures. Evaluation of the next five patients will determine if earlier intervention can further enhance the functional benefit.
    Human gene therapy 04/2013; 24(6). DOI:10.1089/hum.2012.250 · 3.76 Impact Factor
  • Source
    • "Our group has developed two investigational clinical gene therapy products for gene augmentation of AAT as a potential therapy for the lung disease by using the recombinant adeno-associated viral vectors (rAAV2-AAT and rAAV1-AAT).7,8 However, because a decrease in the expression of Pi*Z mutant protein is required to halt or ameliorate the hepatocellular damage, researchers tried to downregulate AAT messenger RNA (mRNA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: α-1 antitrypsin (AAT) deficiency can exhibit two pathologic states: a lung disease that is primarily due to the loss of AAT's antiprotease function, and a liver disease resulting from a toxic gain-of-function of the PiZ-AAT (Z-AAT) mutant protein. We have developed several recombinant adeno-associated virus (rAAV) vectors that incorporate microRNA (miRNA) sequences targeting the AAT gene while also driving the expression of miRNA-resistant wild-type AAT-PiM (M-AAT) gene, thus achieving concomitant Z-AAT knockdown in the liver and increased expression of M-AAT. Transgenic mice expressing the human PiZ allele treated with dual-function rAAV9 vectors showed that serum PiZ was stably and persistently reduced by an average of 80%. Treated animals showed knockdown of Z-AAT in liver and serum with concomitant increased serum M-AAT as determined by allele-specific enzyme-linked immunosorbent assays (ELISAs). In addition, decreased globular accumulation of misfolded Z-AAT in hepatocytes and a reduction in inflammatory infiltrates in the liver was observed. Results from microarray studies demonstrate that endogenous miRNAs were minimally affected by this treatment. These data suggests that miRNA mediated knockdown does not saturate the miRNA pathway as has been seen with viral vector expression of short hairpin RNAs (shRNAs). This safe dual-therapy approach can be applied to other disorders such as amyotrophic lateral sclerosis, Huntington disease, cerebral ataxia, and optic atrophies.
    Molecular Therapy 03/2012; 20(3):590-600. DOI:10.1038/mt.2011.292 · 6.23 Impact Factor
Show more